CERES BRAIN Therapeutics is dedicated to treat cerebral diseases with a first focus on rescuing suffering neurons with creatine through an innovative "creatine-to-brain" concept. The first indications are Creatine Transporter Deficiency syndrome, a disabling condition with no treatment affecting children and Amyotrophic Lateral Sclerosis. 
The lead compound CBT101 demonstrated efficacy in a preclinical models models as well as a large cerebral and neuronal distribution in primate.  The CMC reached noticeable milestones with several GMP batches produced.  
Other mitochondriopathies are in the Ceres's pipeline. 
CERES BRAIN Therapeutics has already raised up to 12M€ to move towards the clinical program.

CERES BRAIN Therapeutics

Org chart

Teams

Offices